wpe1E.jpg (33803 bytes)

         Daily Blog - Tiger Software

                            September 8, 2007

           Biotech Series:  Stocks Fighting Prostate Cancer

   GTXI: Tiger Biotech Profits Are As Easy As "1-2-3".

William Schmidt,     - Tiger Software's Creator
      (C) 2007 William Schmidt, Ph. D.  - All Rights Reserved. 

      No reproductions of this blog or quoting from it
      without explicit written consent by its author is permitted.

Back to Home Page - www.tigersoft.com

                             Other Tiger Blogs


                   Send any comments or questions
                    to william_schmidt@hotmail.com

             GTXI: Tiger Biotech Profits Are As Easy As "1-2-3".

                 (1) A Biotech's Bullish Fundamental News,
                 (2) A Rising Stock Market with A Peerless Major Buy
                 and (3) Positive Tiger Technical Readings Indicators on the Stock
                 Will Turn A Nice Profit for You.


          Prostate Cancer strikes one in six Amercian men.  It is the most common form of
        non-skin cancer in America, according to the Prostate Cancer Foundation, with 232,000
        diagnoses and 30,000 fatalities expected a year. It occurs when when the cells of the
        prostate begin to grow uncontrollably. When caught and treated early, prostate cancer
        has a cure rate of over 90%. M
ore than 65% of all prostate cancers are diagnosed
        in men over the age of 65. 
The treatment options can seriously affect a man's life.

               Risk factors: 
African American men are 61% more likely to develop prostate cancer
       compared with Caucasian men.  Men with a single first-degree relative—father, brother
       or son—with a history of prostate cancer are twice as likely to develop the disease, while
       those with two or more relatives are nearly four times as likely to be diagnosed. The risk
       is even higher if the affected family members were diagnosed at a young age.  Diet
       and lifestyle are factors, too. 

               In this series, we look at the key biotech stocks most actively fighting prostate cancer.  
       I show them one at a time with their current TigerSoft chart. If I leave some out, let me know. 
       GTXI is examined first.

       wpeC.jpg (6258 bytes)         GTXI - GTx, Inc.

wpeC.jpg (23308 bytes)   GTX Inc.
  3 Ndunlap Street
  3rd Floor Van Vleet Building
  Memphis, TN 38163
  United States - Map
  Phone: 901-523-9700
  Web Site: http://www.gtxinc.com

GTx, Inc., a biopharmaceutical company,
engages in the discovery, development, and commercialization of small molecules to treat
cancer, osteoporosis and bone loss, muscle
wasting, and other serious medical conditions
in the United States.  Research

       1)   The company markets FARESTON tablets for the treatment of metastatic breast
     cancer in postmenopausal women through wholesale  drug distributors.  
This has relatively
    slim annual sales of $3 million

Its primary drug candidate in clinical development is ACAPODENE, a selective
      estrogen receptor modulator, which is
in pivotal Phase III clinical trials for the treatment
      of multiple serious side effects
of androgen deprivation therapy, for advanced prostate
and for the prevention of prostate cancer in high risk men with precancerous
      prostate lesions called high grade prostatic intraepithelial neoplasia (PIN).
  "Each of these
      indications i
s $500 million-plus [in annual drug sales] if the data is compelling,"
      said Eric Schmidt, analyst for SG Cowen & Co. "If they were able to achieve that
      type of revenue -- $500 million -- this stock would be a home run."

                  3)  GTXI has initiated the Phase IIb clinical trial evaluating Ostarineâ„¢,
     a selective androgen receptor modulator, or SARM, for the treatment of
     cancer cachexia, muscle wasting.
Cachexia is a debilitating, progressive muscle
     wasting condition manifested by unintentional weight loss, muscle weakness, anemia,
     fatigue, and death. More than 50% of cancer patients present with or subsequently
   develop cachexia.  There are no drugs approved by the FDA for the treatment of
     cancer cachexia.


             Currently, an important, but problematic, treatment for prostate cancer is
therapy (ADT) that reduces testosterone production.  GTx's new drug ACAPODENE is in the
       pivotal Phase III trrals.  Its purpose is to treat the serious, even deadly side effects of ADT
       therapy, as patients live longer. 

             In June 2006,   the company announced that patients taking ACAPODENE enjoyed
       a reduction in chlorestol, but is primarily aiming for a reduction in vertebral fractures as
       well as improvements in bone marrow density, osteoporosis and  muscle wasting. 
       data on this trial is expected in the second half of 2007. 
The December 2005 interim report
       showed ACAPODENE did significantly increase Bone Mineral Density (BMD) compared to

       ( )
                      Note that the drug's successful completion of Phase III trials, does not offer definite
       assurance of FDA approval and a successful drug launch.  The cost of the drug was
       one critical concern.  Another was whether enough safety data will be offered the FDA. 
       In that connection, it was auspicious that France's Ipsen has agreed on September
       6, 2005 to pay $30 million to license GTX's Acapodene for European distribution.
www.fiercebiotech.com  ) On July 12, 2007 the  company reported an independent safety
       review of the drug administered in triail to 3,000 patients passed muster

A second and separate Phase III clinical trail continues to evaluate ACAPODENE for
        the "prevention of prostate cancer
in men with high grade prostatic intraepithelial
        neoplasia (PIN). Nearly 1,600 patients with high grade PIN have been enrolled in the trial. 
        GTx anticipates that sufficient cancer events will have occurred to conduct this interim
efficacy analysis by the first quarter of 2008. If the interim efficacy analysis reveals that
        ACAPODENE  20 mg treatment reduces prostate cancer and achieves the pre-specified
        level of statistical significance, GTx plans to submit a New Drug Application....


         The biggest institutional shareholder is FMR CORPORATION (FIDELITY MANAGEMENT
         & RESEARCH CORP) with 5.228.561 shares (15% of outstanding stock) valued at $84.65
         million.  Fidelity's Biotech Fund does not list this in its top ten holdings, but has 253,273
         shares. ..  By far, the biggest individual owner is Joseph R Hyde III with 6.240.028 shares. 
         He is on the Board of Directors of GTx, Inc and FDX    The company's two co-founders,
         Dr. Mitchell S Steiner (46) and Marc S Hanover (46) have 26,500 and 105,138 shares.

                                                       Techniques for Trading GTXI

Tiger Software offers pioneering research into how to trade successfully stocks like
       GTXI.  Consider how use the relative strength indicator defined as "RSQ", the quotient of
       GTXI divided by BBH (Biotech Index).  First, look at the GTXI chart for 2006.  The
       RSQ broke out significantly ahead of price.
  The stock was only 10.81.  The earlier
       Tiger "Buy B16" signal confirmed the relative strength breakout.  The clustered major
       Tiger Buys that soon followed showed a very nice move was taking place.

                                                                            GTXI - 2006

wpeC.jpg (45920 bytes)
                                                                    GTXI - 2007

With the stock having nearly doubled in four months, we should be ready to
         take profits.  See below how Tiger's RSQ Indicator broke its uptrendlne ahead of
         the stock's breaking of its 50-day moving average.  Many traders use the popular
         50-day moving average to identify intermediate-term trend changes.

The RSQ (GTXI/BBH) for GTXI is now going sidewise.  We would be watching
       for a breakout to signify that a powerful new uptrend has started given the stock's
       fundamental outlook. 
wpeF.jpg (44599 bytes)

                                                              GTXI - 2006

                    Traders should also have noted the very high readings in October from the
           Tiger's Accumulation Index.
  In these circumstances, such readings were reason enough
           to buy the stock in anticipation of a price breakout to a new high over 12.5.  Afterwards,
           the actual achievement of the new high in November 2006 was another signal to buy
           the stock. GTXI here was an an attractive way to invest in the biotech field in the then
           rising general stock market.  The first dip in January stopped just above its rising
           50-day moving average.  The resumption of the rally from this point was very constructive.

wpe10.jpg (47588 bytes)

                                                          GTXI - 2007

                           In April 2007 the stock turned down and on high (red) volume closed decisively
                below its (blue) 50-day moving average.  With the stock having doubled in five months,
                profits might reasonably have been taken when its 50-day moving average was broken. 
                Even better, was taking the Tiger "S27" as a major Sell a month earlier.

                          The chart now shows an emerging 10 month-wide head and shoulders top.
                The neckline-support is at 14.  The right and left shoulders both have apexes at 19.  
                That level constitutes resistance.  The fact that the stock's 50-day moving average
                 is declining should keep us away from the stock, though it is a positve that the
                Accumulation Index is quite positive.

         wpe11.jpg (48998 bytes)


                                                                            end of report


                                           The next Blog will take up:

Dendreon's prostate cancer drug Provenge is in high demand and has proven to extend life for several months. Instead of buying the common I suggest taking a look at the January 2008 $7.50 calls for $1.60.



             Drugs at the Clinical Stage -- In the Pipeline


The Biotech-100 Index includes 100 small cap biotechnology stocks whose product drug pipeline contain at least one drug in either phase II and/or Phase III clinical development. There is a 90% chance of rejection in early-stage phase I clinical trials; a 50% chance in phase II; 20% in phase III; and 10% post-phase III. Companies that are in phase II and III tend to show great promise but still have a high degree of volatiliy.


Pipeline Drugs Company Symbol


ABX-EGF (panitumumab) Abgenix ABGX targets the epidermal growth factor receptor (EGFr), which is over-expressed in a variety of cancers including lung cancer, breast cancer, bladder, pancreatic, colorectal cancer, kidney and head and neck cancer.
ABX-MA1 Abgenix ABGX ABX-MA1 targets a protein called MUC18, a cell-surface adhesion molecule that is highly expressed on metastatic melanoma cells but not on normal skin cells
ACP-103 Acadia ACAD Parkinson's Disease, adjunctive therapy for schizophrenia (Hallucinations, Psychoses)
Onconase (ranpirnase) AlfaCell ACEL Ribonuclease anti-cancer drug,
Entereg (alvimopan) Adolor ADLR pain management of POI and OBD
lidocaine patch Adolor ADLR postoperative incisional pain
cetrorelix Æterna Zentaris Inc AEZS oncology and endocrine therapy
perifosine Æterna Zentaris Inc AEZS signal transduction inhibitor (cancer)
Teverelix,, D63153 Æterna Zentaris Inc AEZS prostate cancer -BPH
Lobaplatin Æterna Zentaris Inc AEZS Small cell lung cancer, breast, chronic myelogenous leukemia (CML)
Neovastat Æterna Zentaris Inc AEZS Non-small cell lung cancer
RC-3095 Æterna Zentaris Inc AEZS Multiple cancers
AG-858 Antigenics Inc. AGEN Chronic myelogenous leukemia (CML)
Oncophage Antigenics Inc. AGEN Metastatic melanoma, Kidney cancer (renal cell carcinoma)
AG-702 Antigenics Inc. AGEN Genital herpes
V -Protectants® (AGI-1067) Atherogenics AGIX chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma
Vivitrex Alkermes ALKS Alchol Dependence
Medisorb Alkermes ALKS Diabetes
AIR Insulin Alkermes ALKS Diabetes
AIR Epinephrine Alkermes ALKS Anaphylaxis
Pexelizumab Alexion ALXN Cardiopulmonary Bypass, Acute Myocardial Infarction
Eculizumab Alexion ALXN Nephritis, Dermatomyositis , Paroxysmal Nocturnal Hemoglinuria
Efaproxiral Allos Therapeutics ALTH Brain metastases from breast cancer, non-small cell lung cancer, cervical cancer
PDX (pralatrexate) Allos Therapeutics ALTH non-small cell lung cancer, Mesothelioma, non-Hodgkin's Lymphoma
SYMLIN® (pramlintide acetate) Amylin AMLN synthetic version of human amylin -glucose control with type 1 diabetes
exenatide (synthetic exendin-4) Amylin AMLN type 2 diabetes
Isatoribine (ANA245) Anadys ANDS Hepatitis C
ANA 380 Anadys ANDS Hepatitis B
Oral Prodrug ANA971 Anadys ANDS reduce the risk of HCV relapse
AMD3100 AnorMED AOM.TO stem cell mobilizer
AMD070 AnorMED AOM.TO chemokine inhibitor for HIV
Insegia(G17DT immunogen) Aphton Corp APHT cancer and gastrointestinal disease
AP23573 Ariad ARIA solid tumor and blood malignancies
TP10 Avant AVAN Cardiac Surgery
CETi-I Avant AVAN Cholesterol Management
CholeraGarde Avant AVAN Cholera
Ty800 Avant AVAN Typhoid Fever
Injectable Anthrax Avant AVAN Anthrax
Therapore Avant AVAN HIV
Resten-NG Avi Biopharma AVII cardiovascular restenosis
Avicine Avi Biopharma AVII vaccine -- anti-hCG immune response targeting hCG-producing cancer cells
NeuGene compounds Avi Biopharma AVII anti-sense drugs for cancer, polycystic kidney disease, and viral diseases
Neurodex Avanir AVN pseudobulbar affect, neuropathic pain
Avanir Avanir AVN Asthma
AV201 Avigin AVGN severe Parkinson's disease
Phenserine Axonyx AXYX Alzheimer's disease
Theratope Vaccine Biomira BIOM colorectal, metastatic breast cancer
BLP25 Liposome Vaccine Biomira BIOM Prostate, non-small cell lung cancer
Modrenal Bioenvision BIVN Prostate Cancer
Clofarabine (CLOLAR) Bioenvision BIVN pediatric acute lymphoblastic leukemia, solid Tumors
Velostan Bioenvision BIVN post-menopausal advanced breast cancer, bladder cancer
virostat Bioenvision BIVN hepatitis C
GVAX (vaccine) Cell Genesys CEGE Prostate, lung, pancreatic, leukemia, myeloma
CG7870 Oncolytic Virus Therapy Cell Genesys CEGE Prostate cancer
Daptomycin (cubicin) Cubist CBST soft tissue infection, infective endocarditis
HepeX-B Cubist CBST prevention of infection by hepatitis B in liver transplant
Oracea Collagenex Pharmaceuticals Inc CGPI rosacea
E2F Decoy Corgentech CGTK Coronary Bypass Graft, Arterio-Venous Graft
mifepristone ( Corlux) Corcept CORT Psychotic major depression, Alzheimers
XYOTAX Cell Therapeutics CTIC non-small cell lung cancer (NSCLC) and ovarian cancer
Pixantrone Cell Therapeutics CTIC non-Hodgkin's lymphoma (NHL
TRISENOX Cell Therapeutics CTIC relapsed/refractory acute promyelocytic leukemia
CT-2106 Cell Therapeutics CTIC anti-cancer drug
Ventavis CoTherix Inc CTRX pulmonary arterial hypertension
Ranexa CV Therapeutics Inc CVTX Chronic Angina
Regadenoson CV Therapeutics Inc CVTX Myocardial Perfusion Imaging
Tecadenoson CV Therapeutics Inc CVTX (PSVT Atrial Fibrillation)
Adentri CV Therapeutics Inc CVTX congestive heart failure (CHF)
Milnacipran Cypress Biosciences CYPB fibromyalgia syndrome (FMS) and related chronic pain conditions
SB-715992 Cytokinetics CYTK multiple forms of cancer, including combination therapy
provenge Dendreon DNDN prostate cancer vaccine
APC8024(Neuvenge) Dendreon DNDN HER-2/neu positive cancers, including breast, ovarian and colorectal cancers
indiplon DOV Pharmaceuticals DOVP insomnia
bicifadine DOV Pharmaceuticals DOVP pain
ocinaplon DOV Pharmaceuticals DOVP generalized anxiety disorder
DOV 216,303 DOV Pharmaceuticals DOVP depression, anxiety and substance abuse
DOV Diltiazen DOV Pharmaceuticals DOVP Angina and Hypertension
DX-88 Dyax DYAX hereditary angioedema (HAE)
DX-890 Dyax DYAX cystic fibrosis (CF),chronic obstructive airways diseases
Thelin (sitaxsentan) Encysive Pharmaceuticals ENCY pulmonary arterial hypertension (PAH)
BIMOSIAMOSE Encysive Pharmaceuticals ENCY inhaled therapy for asthma, psoriasis and atopic dermatitis
TBC3711 Encysive Pharmaceuticals ENCY endothelin A antagonis
Panzem (2-methoxyestradiol) EntreMed ENMD cancer
XL119 Exelixis EXEL bile duct tumors
Macugen(pegaptanib sodium injection) Eyetech Pharmaceuticals EYET wet form of age-related macular degeneration (AMD)
FM-VP4 Forbes Medi-Tech FMTI cholesterol-lowering and anti-atherosclerotic
Genasense® (oblimersen sodium Genta GNTA melanoma, lung and prostate cancers
Ganite® (gallium nitrate injection). Genta GNTA cancer related hypercalcemia
TNFerade GenVec GNVC Tumor necrosis factor alpha gene
TVAX Telomerase Cancer Vaccine (TVAX) Geron GERN prostate cancer
Aquavan Injection Guilford Pharmaceuticals GLFD mild to moderate sedation for non-invasive procedures
GPI 1485 Guilford Pharmaceuticals GLFD Impotence, Prostate Cancer
GPI 5693 Guilford Pharmaceuticals GLFD neuropathic pain
MyVax Genitope Corp GTOP idotypic vaccine for cancer follicular non-Hodgkin's lymphoma (f-NHL).
ACAPODEME GTX Inc. GTXI Prevention of prostate cancer in men with high grade PIN
Andarine GTX Inc. GTXI Cachexia from various types of cancer
Ostarine GTX Inc. GTXI andropause
HE2100 NEUMUNE Hollis-Eden Pharmaceuticals HEPH protecting the body's bone marrow from acute radiation syndrom
PHOSPHONOL Hollis-Eden Pharmaceuticals HEPH protect against DNA mutations (mutagenesis)-- from radiation
(HE2000) IMMUNITIN Hollis-Eden Pharmaceuticals HEPH Malaria and HIV and preclinical benefit in a number of tuberculosis model
LymphoStat-B Human Genome Sciences HGSI drugs discovered through genomics-based research
Albuferon Human Genome Sciences HGSI hepatitis C, b?? and a broad range of cancers
HGS-ETRI Human Genome Sciences HGSI apoptosis, in cancer cells.
HGS-TR2J Human Genome Sciences HGSI apoptosis, in cancer cells.
480848 Human Genome Sciences HGSI inhibits atherosclerotic plaques
IC485 ICOS ICOS Chronic Obstructive Pulmonary Disease
Tadalafil ICOS ICOS Benign Prostatic Hyperplasia
FluINsure ID Biomedical Corp IDBE vaccine prevention of influenza (flu)
StreptAvax ID Biomedical Corp IDBE vaccine for prevention of diseases caused by group A streptococcus in children
PPV ID Biomedical Corp IDBE vaccine for the prevention of disease caused by Streptococcus pneumoniae (pneumococcus)
Pagocione Indevus Pharmaceuticals IDEV Stuttering
PRO2000 Indevus Pharmaceuticals IDEV HIV and STD Prevention
IP 751 Indevus Pharmaceuticals IDEV Pain and Inflammation
Aminocandin Indevus Pharmaceuticals IDEV Serious Fungal Infections
HuN901-DM1 Immunogen IMGN cancers that express the CanAg antigen
MLN2704 Immunogen IMGN -targets the prostate-specific membrane antigen (PSMA)
Cantuzumab mertansine Immunogen IMGN cancers that express the CanAg antigen
Reverset Incyte Corp INCY HIV
CCR2 Antagonists Incyte Corp INCY Rheumatoid Arthritis, MS, Neuropathic Pain, Atherosclerosis
Sheddase Inhibitors Incyte Corp INCY Cancer
ADVEXIN Introgen Therapeutics INGN Cancer ?? Advexin (adenoviral p53) --bladder cancer--gene therapy -PI
INGN 241 Introgen Therapeutics INGN tumor suppressor product candidate
INGN 225 Introgen Therapeutics INGN tumor vaccine
Visicol InKline Pharamceuticals INKP Constipation
INKP-102 InKline Pharamceuticals INKP Colon cleansing prior to colonoscopy
IB-Stat InKline Pharamceuticals INKP Symptoms associated with Irritable Bowel Syndrome (IBS)
CEA-Scan Immunomedics IMMU targets tumors that have carcinoembryonic antigen (CEA) on their cell membrane
antisense drugs ISIS Pharmaceuticals ISIS ulcerative colitis, diabetes, MS, cardiovascular disease, cancer, psoriasis
diquafosol tetrasodium (INS365 Ophthalmic) Inspire Pharamceuticals ISPH for the treatment of dry eye disease
INS37217-- Respiratory (denufosol tetrasodium) Inspire Pharamceuticals ISPH cystic fibrosis, retinal disease
IN50589 Inspire Pharamceuticals ISPH Antiplatelet for Platelet Inhibition
Sulodexide (KRX-101) Keryx Biopharmaceuticals KERX diabetic nephropathy
Perifosine (KRX-0401) Keryx Biopharmaceuticals KERX multiple forms of cancer
KS 01-019 Kos Pharmaceuticals KOSP dyslipidemia
KS 01-018 Kos Pharmaceuticals KOSP Periperhal Arterial Disease
Azmacort Kos Pharmaceuticals KOSP treatment of asthma as prophylactic therapy
Targretin Ligand Pharmaceuticals LGND non-small cell lung cancer
ONTAK Ligand Pharmaceuticals LGND B- and T-cell non-Hodgkin's lymphomas and chronic lymphocytic leukemia,
Targretin gel Ligand Pharmaceuticals LGND hand dermatitis
LJP 394 La Jolla Pharmaceuticals LJPC Lupus Erythematosus, Systemic Lupus Nephritis
Riquent® (abetimus sodium La Jolla Pharmaceuticals LJPC systemic lupus erythematosus (SLE)
Ceplene Maxim Pharmaceuticals MAXM Advanced Melanoma, Acute Myeloid Leukemia, Renal Cell Carcinoma, Hepatitis C
Medarex Antibodies Medarex MEDX cancer, inflammation, autoimmune and infectious diseases
Anidulafungin Vicuron Pharmaceuticals MICU anti-fungal
Dalbavancin Vicuron Pharmaceuticals MICU glycopeptide class of antibiotics (hospital infections)
Oxazolidinones Vicuron Pharmaceuticals MICU most-difficult-to-treat, multi-drug-resistant bacteria
Deformylase Inhibitors Vicuron Pharmaceuticals MICU antibiotic -- respiratory tract infections
INTEGRILIN® (EPTIFIBATIDE) Millenium Pharmaceuticals MLNM cardiovascular
VELCADE® (bortezomib)- Millenium Pharmaceuticals MLNM lung, breast, prostate cancers
MLN1202,MLN2704 Millenium Pharmaceuticals MLNM Rheumatoid arthritis, multiple sclerosis, inflammation
Technosphere Insulin System MannKind Corp MNKD pulmonary delivery system for diabetes
Enoximone Myogen MYOG Advanced Chronic Heart Failure
Ambristentan Myogen MYOG Pulmonary Arterial Hypertension
Darusentan Myogen MYOG Uncontrolled Hypertension
Flurizan Myriad Genetics Inc MYGN Alzheimer's, cancer
StaphVAX Nabi Biopharmaceuticals NABI Vaccine for staphylococcus infections
NicVax Nabi Biopharmaceuticals NABI Vaccine for smoking cessation vaccine
Civacir Nabi Biopharmaceuticals NABI Hepatitis C antibody-based therapies
IL13-PE38QQR NeoPharm Inc NEOL Glioblastoma Multiforme brain tumor
Liposomal SN38 NeoPharm Inc NEOL Advanced cancers; including colorectal and lung
Liposomal c-raf Antisense Oligonucleotide NeoPharm Inc NEOL Advanced cancers; including pancreatic (monotherapy and combination with radiation/chemotherapy)
Liposomal Paclitaxel-Easy-to-use NeoPharm Inc NEOL Advanced cancers; including breast cancer, lung and ovarian
Indiplon Neurocrine Biosciences NBIX insomnia via inhibitory neurotransmitter --- GABA
CRF Receptor Antagonis Neurocrine Biosciences NBIX Anxiety and depression
NBL- 5788 Neurocrine Biosciences NBIX Multiple Sclerosis
Urocortin 2 Neurocrine Biosciences NBIX Acute congestive heart failure (CHF)
GnRH antagonists Neurocrine Biosciences NBIX Endometriosis
PREOS® (recombinant human parathyroid hormone) NPS Pharmaceuticals NPSP treatment of osteoporosis
Teduglutide NPS Pharmaceuticals NPSP gastrointestinal disorders including Short Bowel Syndrome
Preotact NPS Pharmaceuticals NPSP Osteoperosis
Calcilytics NPS Pharmaceuticals NPSP Osteoperosis
GlyT-1 NPS Pharmaceuticals NPSP Schizophrenia
Fibrillex Neurochem Inc. NRMX AA Amyloidosis
Alzhemed Neurochem Inc. NRMX Alzheimer's Disease --inhibit the Amyloid Cascade
Cerebril Neurochem Inc. NRMX Hemorrhagic stroke due to cerebral amyloid angiopathy
Memantine (Namenda) Neurobiological Tech NTII progressive neurological impairment due to neuronal injur
XERECEPT -- natural human peptide CRF Neurobiological Tech NTII inhibitor of swelling, or edema
VIPRINEX™ (ancrod) Neurobiological Tech NTII stroke patients -- anticoagulation
BiDil NitroMed NTMD Heart failure, or end-stage cardiovascular disease
Alfimeprase Nuvelo NUVO thrombolytic agent or blood clot dissolver
rNAPc2 Nuvelo NUVO Factor VIIa / Tissue Factor Inhibitor
ARC183 Nuvelo NUVO DNA-based direct thrombin inhibitor-- anticoagulant / anti-thrombotic
BAY 43-9006 Onyx Pharmaceuticals ONXX advanced renal (kidney) cancer
Ramoplanin Oscient Pharmaceuticals OSCI Clostridium difficile-associated diarrhea
FACTIVE Oscient Pharmaceuticals OSCI Intravenous-- Bacterial Infections
CA4P (combretastatin)-- Oxigene OXGN Vascular targeting agent ??CK PHASE
Motexafin gadolinium Pharmacyclics Inc. PCYC anti-cancer product
Motexafin lutetium Pharmacyclics Inc PCYC reduce or eliminate “vulnerable plaque ”
Apan Praecis Pharmaceuticals PRCS Alzheimer's Disease
PPI-2458 Praecis Pharmaceuticals PRCS Non-Hodgkin's Lymphoma/RA
MNTX Progenics Pharmaceuticals PGNX Advanced medical ilness, post-operative ileus, chronic pain
GMX Progenics Pharmaceuticals PGNX Melanoma Cancer
PSMA Progenics Pharmaceuticals PGNX prostate cancer
PRO542 Progenics Pharmaceuticals PGNX HIV
PRO 140 Progenics Pharmaceuticals PGNX HIV
Trexima POZEN Inc. POZN migraine pain
OXYTREX Pain Therapeutics Inc. PTIE severe chronic pain, such as low back, osteoarthritic pain or cancer pain
REMOXY Pain Therapeutics Inc. PTIE proprietary abuse-resistant version of time-release oxycodone
PTI-901 Pain Therapeutics Inc. PTIE chronic Irritable Bowel Syndrome (IBS).
AXOKINE IL-1 Regeneron Pharmaceuticals REGN potential treatment of obesity
VEGF Trap Regeneron Pharmaceuticals REGN inihibits tumor blood vessel growth
L-4/13 Trap Regeneron Pharmaceuticals REGN treatment in allergy and asthma
IL-1 Trap Regeneron Pharmaceuticals REGN decreases inflammation and blocks cartilage erosion in the joint -- Rhematoid Arthritis
ZADAXIN Sciclone Pharmaceuticals SCLN viral infections-- hepatitis C, and cancer
SCV-07 Sciclone Pharmaceuticals SCLN fight infection
SGN-30 Seattle Genetics SGEN Hodgkin's disease and some types of non-Hodgkin's lymphoma
SGN-15 Seattle Genetics SGEN non-small cell lung cancer
SGN-40 Seattle Genetics SGEN multiple myeloma and non-Hodgkin's lymphoma
XIFAXAN™ (rifaximin) Salix Pharmaceuticals SLXP gastrointestinal- selective, oral antibiotic
ZEGERID Santarus Inc SNTS Heartburn/GERD, Erosive esophagitis, Duodenal ulcers
Orathecin Supergen Inc. SUPG pancreatic cancer
Avicine™ Supergen Inc. SUPG colorectal cancer
Satraplatin Spectrum Pharmaceuticals SPPI Prostate Cancer
SPI-153 Spectrum Pharmaceuticals SPPI Hormone Depenmdent Prostate Cancer
EOquin Spectrum Pharmaceuticals SPPI Bladder Cancer, Radiation Sensitizer
Elsamitrucin Spectrum Pharmaceuticals SPPI Non-Hodgkin's Lymphoma
prosaptide Savient SVNT peripheral neuropathic pain
puricase Savient SVNT symptomatic gout
fibrimage Savient SVNT diagnostic agent for the detection of deep vein thrombosis
I2S Transkaryotic Therapies TKTX Hunter syndrome
GA-GCB Transkaryotic Therapies TKTX Gaucher disease
TELCYTA (TLK286) Telik Inc. TELK advanced ovarian cancer and non-small cell lung cancer (a selective apoptotic agent)
TELINTRA Telik Inc. TELK myelodysplastic syndrome --Bone marrow stimulant
TNX -355 Tanox Inc. TNOX HIV
T-1249 Trimeris Inc. TRMS HIV
Pivanex Titan Pharmaceuticals TTP Refractory Chronic Lymphocytic Leukemia
DITPA Titan Pharmaceuticals   Congestive Heart Failure
Probuphine Titan Pharmaceuticals   Opiate addition
Spheramine Titan Pharmaceuticals   Advanced Parkinson's
Iloperidone Titan Pharmaceuticals   Schizophrenia
Gallium Maltolate Titan Pharmaceuticals   Bone Disease
OvaRex United Therapeutics Corp UTHR Ovarian Cancer
Remodulin United Therapeutics Corp UTHR Critical limb ischemia (CLI)
UT-231B United Therapeutics Corp UTHR Hepatitis C
Celacade Vasogen Inc. VSGN Chronic Heart Failure, Periperheral Arterial Disease
VP025 Vasogen Inc. VSGN Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis
VX-385 Vertex Pharmaceuticals VRTX HIV infection
Merimepodib Vertex Pharmaceuticals VRTX hepatitis C
VX-950 Vertex Pharmaceuticals VRTX hepatitis C
VX-765 Vertex Pharmaceuticals VRTX cytokine inhibitor of interleukin-1 beta converting enzyme (ICE)
VX-702 Vertex Pharmaceuticals VRTX acute coronary syndromes
Pralnacasan Vertex Pharmaceuticals VRTX inflammatory diseases
VX944, VX630 Vertex Pharmaceuticals VRTX Cancer
DNA Vaccines Vical Inc VICL malaria, cytomegalovirus, eboa, west nile virus, hiv, hepatitis
Avanafil Vivus Inc. VVUS erectile dysfunction
ALISTA Vivus Inc. VVUS female sexual arousal disorder
Testosterone MDTS Vivus Inc. VVUS low sexual desire
Evamist Vivus Inc. VVUS symptoms associated with menopause
Neuprex XOMA LTD XOMA immunologic and inflammatory disorders, cancer and infectious diseases
MLN2222 XOMA LTD XOMA coronary artery bypass graft (CABG) surgery patients.
TransMID Xenova Group XNVA Glioblastoma multiforme (GBM)
XR303 Xenova Group XNVA Pancreatic Cancer
XR5944/XR11576 Xenova Group XNVA Solid Tumors
TA-CD Vaccine Xenova Group XNVA Cocaine addition
TA_NIC Vaccine Xenova Group XNVA Nicotine Addiction
Recombinant human Thrombin Zymogenetics Inc. ZGEN control of bleeding associated with various surgical procedures
-TACI-Ig Zymogenetics Inc. ZGEN autoimmune diseases and for advanced B-cell malignancies
Interleukin 21 (IL-21) Zymogenetics Inc. ZGEN cance



seful Links:



FDA advisers back Dendreon's prostate-cancer drug

prevously Provenge delay triggers furor among cancer victims

Sanofi-Aventis and Regeneron say that they have launched two Phase III trials for aflibercept--or
VEGF Trap--with chemotherapy for lung and prostate cancer.

       Novacea cheered on decision to expand cancer trial

An FDA expert committee has dealt a blow to GPC Biotech, concluding
unanimously that regulators should wait for survival data before approving
its prostate cancer drug Orplatna (satraplatin). The Read more...  7/25/2007

      Press Release: Genaera Corporation Discontinues LOMUCIN in Cystic Fibrosis
      and Squalamine in Prostate Cancer Studies

Cytokinetics drug fails in three cancer indications

AstraZeneca is pumping $100 million into its research center in Waltham, MA to boost its R&D efforts for infectious diseases and cancer research. Construction on a 132,000-square-foot facility will begin soon and the facility will open in mid-2009. The expansion will allow AstraZeneca to add 100 more researchers to the 400 it already employs at the research complex.

Since the opening of AstraZeneca R&D Boston, scientists there have discovered three potential drugs that are …

AstraZeneca to invest $100M in R&D site

Prostate Cancer

SPOTLIGHT: Myriad drug fails in trial

Myriad Genetics has dropped one of its development programs for an experimental therapy--MPC-7869--after it failed to perform better than a placebo in a clinical trial for prostate cancer. Myriad researchers say they will continue to study the drug as a therapy for Alzheimer's.


...OncoMethylome Sciences has licensed its prostate cancer test to a subsidiary of Johnson & Johnson.


Hit Counter